Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Poseida Therapeutics Inc (PSTX)

Poseida Therapeutics Inc (PSTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 504,077
  • Shares Outstanding, K 62,155
  • Annual Sales, $ 0 K
  • Annual Income, $ -129,780 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.27
Trade PSTX with:

Options Overview

Details
  • Implied Volatility 121.43%
  • Historical Volatility 41.13%
  • IV Percentile 41%
  • IV Rank 6.48%
  • IV High 898.18% on 01/19/21
  • IV Low 67.63% on 06/18/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 21
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 772
  • Open Int (30-Day) 2,044

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.63
  • Number of Estimates 2
  • High Estimate -0.63
  • Low Estimate -0.64
  • Prior Year -2.28
  • Growth Rate Est. (year over year) +72.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.84 +5.74%
on 08/03/21
9.30 -10.86%
on 07/12/21
-0.50 (-5.69%)
since 07/02/21
3-Month
7.81 +6.15%
on 05/11/21
10.63 -22.01%
on 06/28/21
-0.23 (-2.70%)
since 05/05/21
52-Week
7.63 +8.65%
on 08/24/20
13.98 -40.70%
on 12/28/20
-4.61 (-35.74%)
since 08/05/20

Most Recent Stories

More News
Poseida Therapeutics Appoints Cynthia Collins to Board of Directors

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics...

PSTX : 8.34 (+3.73%)
Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders

, /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics...

PSTX : 8.34 (+3.73%)
Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021

, /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics...

PSTX : 8.34 (+3.73%)
Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting

, /PRNewswire/ --  (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to...

PSTX : 8.34 (+3.73%)
Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board

, /PRNewswire/ -- (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to...

PSTX : 8.34 (+3.73%)
Poseida Therapeutics to Present at BofA Securities 2021 Virtual Health Care Conference

, /PRNewswire/ --Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics...

PSTX : 8.34 (+3.73%)
Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual Meeting

, /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics...

PSTX : 8.34 (+3.73%)
Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences

, /PRNewswire/ --Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics...

PSTX : 8.34 (+3.73%)
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board

, /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics...

PSTX : 8.34 (+3.73%)
Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020

, /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics...

PSTX : 8.34 (+3.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Poseida Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics for high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed...

See More

Key Turning Points

3rd Resistance Point 8.49
2nd Resistance Point 8.37
1st Resistance Point 8.20
Last Price 8.34
1st Support Level 7.91
2nd Support Level 7.79
3rd Support Level 7.62

See More

52-Week High 13.98
Fibonacci 61.8% 11.55
Fibonacci 50% 10.81
Fibonacci 38.2% 10.06
Last Price 8.34
52-Week Low 7.63

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar